Loading...
01/10 16:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed outlook. While the company achieved its first operating profit and improved cash flow, revenues and gross profit declined, and there are concerns over macroeconomic impacts. The Q&A highlights positive operational changes but lacks clarity on AI investments. The share repurchase ruling could strain cash flow. Despite cost reductions and strategic plans for growth, the absence of strong revenue growth or new partnerships tempers the outlook. Without market cap data, a neutral sentiment is prudent.
Total Net Revenues (Q4 2024) RMB3.8 billion, down 6.3% year-over-year due to unfavorable macroeconomic conditions.
Gross Segment Profit (Q4 2024) RMB202.5 million, down 5.5% year-over-year, impacted by the same unfavorable macroeconomic environment.
Total Operating Expenses (Q4 2024) RMB209.8 million, decreased by 50.1% year-over-year, representing 5.5% of net revenues, down from 10.2% due to enhanced operating leverage and efficiency.
Fulfillment Expenses (Q4 2024) 2.7% of net revenues, slightly up from 2.5% in the prior year.
Sales and Marketing Expenses (Q4 2024) 2% of net revenues, down from 4.2% a year earlier.
General and Administrative Expenses (Q4 2024) 0.5% of net revenues, down from 2.4% in the previous year.
Technology Expenses (Q4 2024) 0.4% of net revenues, down from 1.2% in the same quarter 2023.
Non-GAAP Loss on Operations (Q4 2024) RMB2.3 million, improved by 95.8% from RMB55.2 million in the prior year.
Non-GAAP Net Loss Attributable to Ordinary Shareholders (Q4 2024) RMB14.8 million, improved by 74.9% from RMB59 million in the previous year.
Full Year 2024 Net Revenues RMB14.4 billion, down 3.7% year-over-year.
Full Year 2024 Gross Segment Profit RMB829.2 million, down 2.3% year-over-year.
Total Operating Expenses (Full Year 2024) RMB827.1 million, decreased by 31% year-over-year, representing 5.7% of net revenues, down from 8% in 2023.
Fulfillment Expenses (Full Year 2024) 2.6% of net revenues, down from 2.7% in the previous year.
Sales and Marketing Expenses (Full Year 2024) 2.2% of net revenues, down from 3% in 2023.
General and Administrative Expenses (Full Year 2024) 0.5% of net revenues, down from 1.5% a year earlier.
Technology Expenses (Full Year 2024) 0.5% of net revenues, down from 0.8% in 2023.
Income from Operations (Full Year 2024) RMB2.1 million, compared to a loss of RMB351 million in 2023.
Non-GAAP Income from Operations (Full Year 2024) RMB22.3 million, compared to a loss of RMB123.9 million in 2023.
GAAP Net Loss Attributable to Ordinary Shareholders (Full Year 2024) 0.3% of net revenues, improved from 1.1% a year ago.
Cash Position (as of December 31, 2024) RMB518.3 million in cash and cash equivalents, restricted cash, and short-term investments.
Operating Cash Flow (Full Year 2024) Achieved positive operating cash flow for the first time.
New Product Introductions: Introduced 6,598 new products in 2024 contributing over RMB905 million in GMV.
Market Expansion: Expanded last mile delivery coverage to additional metropolitan areas including Wuhan, Guangzhou, Chongqing and Tianjin.
Fulfillment Center Expansion: Added seven new fulfillment centers in Q4, increasing total to 18, enabling delivery to over 300 major cities within 24 hours.
Operational Efficiency: Achieved first ever operational profitability with income from operations reaching RMB2.1 million, a turnaround from a loss of RMB350.1 million in 2023.
Cost Reduction: Reduced total operating expenses by 31% year-over-year, bringing them to 5.7% of revenues.
Technology Investments: Strengthened digital capabilities, improving forecasting accuracy from 71% to 82%.
Strategic Shift: Focused on digital transformation and AI-driven solutions to enhance operational efficiency and customer engagement.
Growth Strategy: Plans to expand fulfillment center footprint by adding at least 15 more centers in 2025.
Macroeconomic Pressures: Economic uncertainties in China have led to cautious consumer behavior, slowing discretionary spending, and dampening retail sales growth, impacting the healthcare sector.
Healthcare Reforms: Ongoing healthcare reforms, including adjustments to individual medical accounts and heightened regulatory oversight, present short-term challenges as the industry adapts to new policies.
Market Competition: Increased competition due to aggressive expansion during the pandemic has resulted in a decline in total retail pharmacy sales by 2.2% in 2024, leading to falling revenues per store.
Profitability Challenges: Newer stores in growth phases face pressure on short-term profitability, with large pharmacy chains experiencing significant declines in net profit.
Regulatory Uncertainties: Policy execution remains uneven across provinces, creating uncertainties and delays in medical reform implementation.
Supply Chain Challenges: The company is enhancing its supply chain infrastructure but faces challenges in managing costs and operational inefficiencies.
Investor Relations: The company has outstanding amounts owed to investors and is negotiating repayment schedules, which could impact financial flexibility.
Arbitration Outcome: An arbitration ruling requiring the company to repurchase shares for RMB30 million plus interest could have implications for cash flow.
Operational Profitability: Achieved first-ever operational profitability and positive operating cash flow in 2024.
Cost Reduction: Reduced total operating expenses by 50.1% in Q4 and 31% for the full year 2024.
Digital Transformation: Integrated leading technologies across operations to enhance efficiency and service quality.
Supply Chain Infrastructure: Strengthened supply chain infrastructure with the expansion of fulfillment centers and logistics network.
AI Integration: Invested in AI-driven analytics and automation to enhance operational efficiency and customer engagement.
Kunpeng Network: Expanded logistics network to streamline services and lower costs.
Franchise Fulfillment Centers: Planned to add at least 15 more fulfillment centers in 2025.
Revenue Outlook: Expect continued growth in healthcare consumption driven by China's aging population and healthcare reforms.
Operational Efficiency: Focus on driving further cost reductions and enhancing profitability through scalability.
Customer Engagement: Initiatives like flash sales and GROW Project to stimulate customer loyalty and engagement.
Investment in Technology: Continued investment in technology to maintain competitive advantage and operational excellence.
Future Capex: Plans to expand fulfillment center footprint and enhance supply chain capabilities.
Share Repurchase: The company has reached agreements or obtained commitment letters from investors representing approximately 97% of total amount to reschedule their repayments, allowing for phased repayments over extended periods if the holders exercise their redemption rights.
Redemption Request: The company has received a redemption request from certain investors, requiring the company’s Hong Kong subsidiary to repurchase the investment share in one pharmacy technology for RMB30 million plus accrued interest.
The earnings call presents a mixed outlook. While the company achieved its first operating profit and improved cash flow, revenues and gross profit declined, and there are concerns over macroeconomic impacts. The Q&A highlights positive operational changes but lacks clarity on AI investments. The share repurchase ruling could strain cash flow. Despite cost reductions and strategic plans for growth, the absence of strong revenue growth or new partnerships tempers the outlook. Without market cap data, a neutral sentiment is prudent.
The earnings call highlighted significant improvements in financial performance, including the first annual operating profit and positive cash flow, driven by reduced expenses and enhanced efficiency. Despite a slight revenue decline, management's optimistic guidance and strategic focus on AI and digital transformation support a positive outlook. The Q&A revealed confidence in sustained profitability and cost optimization, although some responses lacked clarity. Overall, the positive financial turnaround and strategic initiatives suggest a positive stock price movement, offsetting concerns about unclear partnership plans.
The earnings call reflects a mixed sentiment. While there are positive aspects like operational profitability, improved gross profit margins, and positive cash flow, there are significant challenges such as macroeconomic pressures, regulatory issues, and flat revenue growth. The Q&A section indicates optimism but lacks clarity in some responses. The strategic partnership and investment in technology are positives, but the economic uncertainties and outstanding liabilities pose risks. Overall, the sentiment is neutral with a potential slight positive tilt due to operational improvements and strategic initiatives.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
